Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced its participation in TD Cowen’s Genetic Medicines & RNA Summit.
Laurent Fischer, M.D., the company's president and CEO, will engage in a fireside chat at the summit on June 21, 2024, at 10:00 a.m. ET.
The event will be webcasted live and accessible via Adverum's website under the Investors section, with a replay available for at least 30 days post-event.
- Participation in a high-profile event like TD Cowen’s Genetic Medicines & RNA Summit enhances the company's visibility in the biotech and investment community.
- Webcast availability ensures broad access to the presentation, potentially engaging a wider audience, including investors and stakeholders.
- The press release lacks substantial new information regarding financial performance, clinical trial updates, or business development initiatives, which may lead to impact on stock performance.
- Reliance on the event's exposure without tangible business progress or data could be seen as a lack of significant updates.
REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at TD Cowen’s Genetic Medicines & RNA Summit on Friday, June 21, 2024 at 10:00 a.m. ET.
The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
What is the date of Adverum Biotechnologies' presentation at TD Cowen’s Genetic Medicines Summit?
How can I access the webcast of Adverum Biotechnologies' presentation?
How long will the replay of Adverum Biotechnologies' presentation be available?
Who is representing Adverum Biotechnologies at TD Cowen’s Genetic Medicines & RNA Summit?
What is the stock symbol for Adverum Biotechnologies?
